|
| 36603541 | Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. | J Clin Oncol | 2023 |
| 37377901 | Integrative Metatranscriptomic Analysis Reveals Disease-specific Microbiome-host Interactions in Oral Squamous Cell Carcinoma. | Cancer Res Commun | 2023 |
| 30651561 | Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. | Nat Commun | 2019 |
| 18632442 | The Role of Plerixafor (AMD3100) in Mobilizing Hematopoietic Progenitor Cells in Patients with Hematologic Malignancies. | Support Cancer Ther | 2006 |
| 15613695 | Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. | J Clin Oncol | 2005 |
| 18632429 | Denosumab (AMG 162), a Fully Human Monoclonal Antibody Against RANK Ligand Activity. | Support Cancer Ther | 2005 |
| 18632428 | Therapeutic use of the cannabinoid receptor antagonist rimonabant in weight loss and smoking cessation. | Support Cancer Ther | 2005 |
| 18632427 | Highlights from: The 9th International Congress on Hematologic Malignancies, Whistler, BC, Canada. | Support Cancer Ther | 2005 |
| 18628191 | Palifermin is efficacious in reducing oral mucositis induced by intensive cancer therapy. | Support Cancer Ther | 2005 |
| 18628190 | Highlights from: The 46th Annual Meeting of the American Society of Hematology; San Diego, CA. | Support Cancer Ther | 2005 |
| 18628175 | Role of psychostimulants in the management of cancer-related fatigue in patients with advanced cancer. | Support Cancer Ther | 2005 |
| 18628174 | Deferasirox (ICL670; Exjade(R)), a Novel Orally Available Iron Chelator for Correction of Transfusion-Associated Iron Overload. | Support Cancer Ther | 2005 |
| 18628173 | Highlights from: The 41st Annual Meeting of the American Society of Clinical Oncology; Orlando, FL. | Support Cancer Ther | 2005 |
| 18628164 | Novel thrombopoetin mimetic agents with potential to ameliorate chemotherapy-induced thrombocytopenia. | Support Cancer Ther | 2005 |
| 16197618 | Preoperative chemoradiation therapy shows improved clinical benefit in patients with rectal cancer. | Clin Colorectal Cancer | 2005 |
| 15636687 | Meeting highlights 46th annual meeting of the American Society of Hematology December 2004 San Diego, California. | Clin Lymphoma | 2004 |
| 18628183 | Rasburicase for prevention of hyperuricemia and tumor lysis syndrome. | Support Cancer Ther | 2004 |
| 18628182 | New strategies for the treatment of chemotherapy-induced diarrhea. | Support Cancer Ther | 2004 |
| 18628153 | Incidence of thromboembolism and role of low molecular weight heparin in prolonging survival in patients with advanced malignancies. | Support Cancer Ther | 2004 |
| 18628152 | Prevention and management of osteonecrosis of the jaw associated with bisphosphonate therapy. | Support Cancer Ther | 2004 |
| 18628151 | Kyphoplasty in the management of cancer-associated vertebral compression fractures. | Support Cancer Ther | 2004 |
| 18628143 | Prophylactic pegfilgrastim significantly reduces febrile neutropenia during moderately myelosuppressive chemotherapy. | Support Cancer Ther | 2004 |
| 18628144 | Current strategies to minimize treatment-associated hot flashes in patients with breast cancer. | Support Cancer Ther | 2004 |
| 18628142 | Highlights from: The 40th Annual Meeting of the American Society of Clinical Oncology; New Orleans, LA. | Support Cancer Ther | 2004 |
| 18628135 | Impact of correction of anemia on clinical outcome in patients with cancer: recent data from head and neck and breast cancer trials. | Support Cancer Ther | 2004 |
| 18628134 | Control of chemotherapy-induced emesis with 5-hydroxytryptamine-3 antagonists. | Support Cancer Ther | 2004 |
| 18628133 | Highlights from: The 2nd Annual Future of Supportive Therapy in Oncology; St. Kitts, West Indies. | Support Cancer Ther | 2004 |
| 12688355 | Evaluation of thymic output by measurement of T-cell-receptor gene rearrangement excisional circles (TREC) in patients who have received fludarabine. | Leuk Lymphoma | 2003 |
| 18628127 | The use of recombinant human keratinocyte growth factor (palifermin) to ameliorate treatment-induced mucositis. | Support Cancer Ther | 2003 |
| 18628126 | Early initiation of epoetin alfa prevents development of chemotherapy-associated anemia and preserves quality of life. | Support Cancer Ther | 2003 |
| 18628125 | Highlights from: The 39th Annual Meeting of the American Society of Clinical Oncology; Chicago, Illinois. | Support Cancer Ther | 2003 |
| 11986207 | Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. | Blood | 2002 |
| 12482329 | Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. | Clin Colorectal Cancer | 2002 |
| 11970762 | Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma. | Clin Lymphoma | 2002 |
| 11707843 | A multicenter trial of infusional etoposide, doxorubicin, and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma. | Clin Lymphoma | 2001 |
| 11675520 | Activity of infusional etoposide, vincristine, and doxorubicin with bolus cyclophosphamide (EPOCH) in relapsed Hodgkin's disease. | Oncologist | 2001 |
| 10442187 | Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. | Ann Oncol | 1999 |
| 10233841 | Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma. | Am J Pathol | 1999 |
| 9824048 | Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma. | Cancer Gene Ther | 1998 |
| 9704735 | Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. | J Clin Oncol | 1998 |
| 8791621 | Vectors with bidirectional reporter genes for studying divergent promoters. | Methods Enzymol | 1996 |
| 8695836 | A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. | Blood | 1996 |
| 8604484 | Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation. | Transfusion | 1995 |
| 8251159 | A rapid screening method for bacteria containing firefly luciferase plasmids. | Biotechniques | 1993 |
| 8515068 | Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation. | J Immunol | 1993 |
| 1325163 | Dual reporter vectors for determination of activity of bidirectional promoters. | Biotechniques | 1992 |
| 1335792 | Epstein-Barr virus and Burkitt's lymphoma. | Semin Cancer Biol | 1992 |
| 1403054 | Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. | J Clin Oncol | 1992 |
| 1807155 | A chemiluminescent assay for quantitation of beta-galactosidase in the femtogram range: application to quantitation of beta-galactosidase in lacZ-transfected cells. | Anal Biochem | 1991 |
| 1743629 | Ifosfamide in the treatment of high-grade recurrent non-Hodgkin's lymphomas. | Hematol Oncol | 1991 |